ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4

ImmunoGen, Inc. Initiates Phase II Clinical Trial of HuC242-DM4: "CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops novel targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced today that the Company has initiated a Phase II clinical study that evaluates its huC242-DM4 compound for the treatment of stomach (gastric) cancer. Patient dosing in this study began earlier this week. Stomach cancer is one of the most common cancers on a global basis, and is one of the leading causes of cancer deaths."